3JC48-3

3JC48-3 is a small molecule inhibitor designed to target the proto-oncogene c-Myc by disrupting its obligate heterodimerization with its partner protein, MAX. Because c-Myc lacks a stable tertiary structure, direct therapeutic targeting is difficult; 3JC48-3 addresses this by preventing the formation of the MYC/MAX complex, which is essential for its function as a transcription factor. In preclinical studies involving prostate cancer cell lines and patient-derived xenograft (PDX) models, the compound demonstrated dose-dependent inhibition of tumor growth and viability. This effect is associated with the upregulation of Protein Kinase D1 (PrKD1) expression and kinase activity. Developed by researchers at Creighton University and the University of Florida, 3JC48-3 has shown a favorable safety profile in mice at doses up to 100 mg/kg without dose-limiting toxicity.